Evidence map›Paper›PMID 40415095›Full record

ArticleScientific reports2025

Locoregional radionuclide therapy of glioblastoma with [

Huan Ma, Tianzhen Ye, Guofeng Qu, Yilin Qin, Jiali Liao, Yuanyou Yang, Wei Zhang, Ning Liu, Feize Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Monte Carlo microdosimetry ofEJNMMI physics · 2026
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huan MaDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, P. R. China.
Tianzhen YeKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, P. R. China.
Guofeng QuKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, P. R. China.
Yilin QinKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, P. R. China.
Jiali LiaoKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, P. R. China.
Yuanyou YangKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, P. R. China.
Wei ZhangDepartment of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, P. R. China.
Ning LiuKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, P. R. China.
Feize LiKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu, 610064, P. R. China. lifeize@scu.edu.cn.

Funding

National Natural Science Foundation of China 12475349Youth Talent Fund of Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital 2022QN32
6 · The paper itself

Abstract

Glioblastoma is the most common and aggressive tumor of the central nervous system. Locoregional administration of therapeutic radiopharmaceuticals appears to be a promising modality for recurrent glioblastomas. In this study, fibroblast activation protein alpha (FAPα) targeting molecule fibroblast activation protein inhibitor-04 (FAPI-04) was conjugated to polydopamine (PDA) nanoparticles, and then, α-emitter astatine-211 was labeled onto the nanocomposite to form [

Indexed as

AstatineBrain NeoplasmsGlioblastomaIndolesMembrane ProteinsPolymersRadiopharmaceuticalsAnimalsApoptosisCell Line, TumorCell SurvivalHumansMiceMice, NudeNanoparticlesXenograft Model Antitumor AssaysAstatineAstatine-211IndolesMembrane ProteinsPolymersRadiopharmaceuticalsAstatine-211Fibroblast activation protein inhibitorGlioblastomaPolydopamineTargeted alpha therapy

Identifiers

PMID40415095
PMCPMC12104461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.